公司資料
Prothena 股價、新聞與催化劑
- 股票代碼:
- PRTA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Ireland
股票表現
9.39 USD (-0.63%)
收盤價
最後更新: 2026年8月24日
481M USD
市值
股價為何變動
As of Aug 24, 2026, PRTA closed down 0.63% at $9.39. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Prothena is a neuroscience and protein-dysregulation biotechnology company focused on rare neurodegenerative and amyloid-related diseases. Its pipeline is aimed at high-unmet-need areas where clinical data can quickly change the market’s view.
所在地與產業分類
Headquartered in Ireland and listed on NASDAQ, Prothena has a transatlantic biotech profile. It sits in neuroscience and protein-misfolding biology.
商業模式特徵
The company’s value is driven by clinical readouts, partnership activity, and the ability to translate deep biology into differentiated programs. Investors watch safety, efficacy, and the durability of its lead scientific hypotheses.
生技產業定位
Prothena sits in the high-risk, high-catalyst neuroscience niche of biotech. The stock can move sharply around data because the programs are small in number but potentially large in impact.
未來催化劑
- Prothena's catalysts are PRX012 and the tau/amyloid program cadence, with any next clinical update helping decide whether the neuroscience story still has real optionality. The market wants human data that can support a longer development path rather than another broad platform pitch.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。